Key result
OAGB and RYGB demonstrate early safety with no deaths or ICU admissions at 3 months.
Why the study?
Prospective studies comparing Roux-en-Y gastric bypass and one-anastomosis gastric bypass are lacking, and the metabolic effects of bariatric surgery and weight loss require deeper understanding.
Does one-anastomosis gastric bypass compared to Roux-en-Y gastric bypass improve weight loss and metabolic outcomes in bariatric patients?
RCT (n=60)
Open-label
Block randomization using sealed opaque envelopes
Yes
Does one-anastomosis gastric bypass compared to Roux-en-Y gastric bypass improve weight loss and metabolic outcomes in bariatric patients?
The interim analysis of the RYSA trial indicates that both Roux-en-Y and one-anastomosis gastric bypass can be safely performed in bariatric patients.
Answers are grounded in this paper and cite their sources.
Both procedures appear safe at interim; extends RCT safety data for bariatric bypass.
INTRODUCTION: There is a lack of prospective studies comparing Roux-en-Y gastric bypass (RYGB) and one-anastomosis gastric bypass (OAGB). Also, the effects of bariatric surgery and weight loss need a deeper understanding through metabolic studies. We describe the trial protocol and interim analysis of a prospective randomized controlled study comparing RYGB and OAGB: the RYSA trial. MATERIALS AND METHODS: In total, 120 bariatric patients will be randomized between RYGB and OAGB in two academic centers. All patients will be followed up for 10 years with analysis and measurements of weight, comorbidities, blood tests, body composition and questionnaires. Extensive metabolic analyses (mixed meal tests, energy expenditure, biopsies of muscle and subcutaneous fat, urine, saliva and fecal samples) will be carried out in the Obesity Research Unit, University of Helsinki, for all patients treated at the Helsinki University Hospital (80 patients) at baseline, 6 months and 12 months. Bile reflux will be studied for the OAGB group at the Helsinki University Hospital at 6 months with gastroscopy and scintigraphy. RESULTS: At an interim analysis at 3 months (half-way) through recruitment (30 RYGB and 30 OAGB patients) there have been no deaths and no intensive care unit admittances. One patient in both groups required additional gastroscopy, with anastomosis dilatation in the RYGB group but with no additional intervention in the OAGB group. CONCLUSION: The trial can be safely carried out. Recruitment is estimated to be complete by the end of 2019. TRIAL REGISTRATION: Clinical Trials Identifier NCT02882685. Registered on August 30th 2016.
No takes yet. Share an insight, caveat, or question.
Saarinen et al. (2019) conducted an RCT in Morbid obesity (n=60). One-anastomosis gastric bypass (OAGB) vs. Roux-en-Y gastric bypass (RYGB) was evaluated on Weight loss 2 years after the operation (percentage excess weight loss and percentage total weight loss). At a 3-month interim analysis, both one-anastomosis gastric bypass and Roux-en-Y gastric bypass were performed safely with no deaths or intensive care unit admittances among 60 randomized patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: